Bayer Spins Off Respiratory Products To Aerovance
This article was originally published in The Pink Sheet Daily
Former Bayer execs are forming the biotech firm with funding from Apex Partners. Aerovance's lead products are an IL4/13 receptor antagonist for severe asthma entering Phase II, and a recombinant therapeutic protein for chronic obstructive pulmonary disease and cystic fibrosis planned for Phase I.
You may also be interested in...
Financing will fund Phase IIb studies and formula enhancements for uncontrolled asthma compound; expects to partner drug in 2010.
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability